Vogt-Koyanagi-Harada Syndrome in Children – a Case Report

Česká verze

Authors: B. Bušányová; D. Tomčíková; A. Gerinec
Authors place of work: Práca bola prednesená na X. sympóziu detskej oftalmológie 27. –28. 5. 2011 v Bratislave. ; Klinika detskej oftalmológie DFNsP-LF UK, Bratislava, prednosta kliniky prof. MUDr. Anton Gerinec, CSc.
Published in the journal: Čes. a slov. Oftal., 69, 2013, No. 2, p. 81-86
Category: Kazuistika

Práca bola prednesená na X. sympóziu detskej oftalmológie 27.–28. 5. 2011 v Bratislave.

Summary

Vogt-Koyanagi-Harada (VKH) syndrome is a multisystemic disease characterized by granulomatous panuveitis with exsudative retinal detachment and often associated with neurological and skin symptomatology.

In the paper is presented a rare case of probably VHK syndrome in 11-year old caucasian race boy in which was found the bilateral granulomatous panuveitis with exsudative retinal detachment without other systemic symptomatology with typical clinical characteristics and course. Systemic corticosteroid therapy in a patient gradually improved the state, which was then complicated by the occurrence of juxtapapillary subretinal neovascular membrane on both eyes. The following administration of intravitreal injection anti-VEGF (bevacizumab) was modified visual acuity and reduced neovascular membrane.

Key words:
Vogt-Koyanagi-Harada syndrome, children, juxtapapillary choroidal neovascular membrane, anti-VEGF, bevacizumab.

Zdroje

1. Al Hemidan A.I., Tabbara K.F., Althomali T.: Vogt-Koyanagi-Harada associated with diabetes mellitus and celiac disease in a 3-year-old girl. Eur J Ophthalmol, 16; 2006, 1 : 173-7.

2. Benfdil N., Baha Ali T., Jellab B. et al.: Vogt Koyanagi Harada syndrome in children: diagnosis and management. Bull Soc Belge Ophtalmol, 2010; 314 : 15-8.

3. Berker N., Ozdamar Y., Soykan E. et al.: Vogt-Koyanagi-Harada syndrome in children: report of a case and review of the literature. Ocul Immunol Inflamm, 15; 2007, 4 : 351-7.

4. Da Silva, F.T., Damico, F.M., Marin, M.L. et al.: Revised diagnostic criteria for Vogt-Koyanagi Harada disease: considerations on the different disease categories. Am J Ophthalmol, 147; 2009, 2 : 339–345.

5. Farah M.E., Costa R.A., Muccioli C. et al.: Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol, 2002; 134 : 137–139.

6. Foster R.E., Knight C.D., Lowder C.Y.: Subfoveal choroidal neovascular membrane excision in Vogt-Koyanagi-Harada syndrome. Retina, 2000; 20 : 547–549.

7. García L.A., Carroll M.O., Garza León M.A.: Vogt-Koyanagi-Harada syndrome in childhood. Int Ophthalmol Clin, 48; 2008, 3 : 107-17.

8. Julián K., Terrada C., Fardeau C. et al.: Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results. Acta Ophthalmol, 89; 2011, 2 : 179-84.

9. Ketata, A., Ben Zina, Z., Hajji, D. et al.: Two cases of subretinal neovascular membrane in Vogt-Koyanagi-Harada syndrome. J Fr Ophtalmol, 2006, 29 : 302–306.

10. Khalifa Y.M., Bailony M.R., Acharya N.R.: Treatment of pediatric Vogt-Koyanagi-Harada syndrome with infliximab. Ocul Immunol Inflamm, 18; 2010, 3 : 218-22.

11. Kolomeyer, A.M., Roy, M.S., Chu, D.S.: Case Report The Use of Intravitreal Ranibizumab for Choroidal Neovascularization Associated with Vogt-Koyanagi-Harada Syndrome. Case Reports in Medicine, Volume 2011, Article ID 747648, 3 pages, doi:10.1155/2011/747648

12. Lai T.Y., Chan R.P., Chan C.K. et al.: Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye, 23; 2009, 3 : 543-8.

13. Lucena D.R., Paula J.S., Silva G.C. et al.: Incomplete Vogt-Koyanagi-Harada syndrome associated with HLA DRB1*01 in a 4-year-old child: case report. Arq Bras Oftalmol, 70; 2007, 2 : 340-2.

14. Maezawa, N., Yano, A., Taniguchi, M. et al.: The role of cytotoxic T lymphocytes in the pathogenesis of Vogt -⁠ Koyanagi-Harada disease. Ophthalmologica, 185; 1982, 3 : 179–186.

15. Martin T.D., Rathinam S.R., Cunningham E.T. Jr.: Prevalence, clinical characteristics, and causes of vision loss in children with Vogt-Koyanagi-Harada disease in South India. Retina, 30; 2010, 7 : 1113-21.

16. Nowilaty, S.R., Bouhaimed, M.: Photodynamic therapy for subfoveal choroidal neovascularisation in Vogt-Koyanagi-Harada disease. Br J Ophthalmol, 2006; 90 : 982–986.

17. Park H.S., Nam K.Y., Kim J.Y.: Intravitreal bevacizumab injection for persistent serous retinal detachment associated with Vogt-Koyanagi-Harada disease. Graefes Arch Clin Exp Ophthalmol, 249; 2011, 1 : 133-6.

18. Raffa L., Bawazeer A.: Intravitreal bevacizumab injection in a 14-year-old Vogt-Koyanagi-Harada patient with choroidal neovascular membrane. Can J Ophthalmol, 44; 2009, 5 : 615-6.

19. Read, R.W., Yu F., Accorinti, M. et al.: Evaluation of the effect on outcomes oftheroute of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol, 142, 2006, 1 : 119 –⁠ 24.

20. Reed, R.W., Holland, G.N., Rao N.A. et al.: Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol, 131; 2001, 5 : 647 –⁠ 52.

21. Setiabudiawan, B., Karfiati, F., Ghrahani, R. et al.: Vogt-Koyanagi-Harada disease in an 8-year-old boy. 1; 2011, 2 : 98–103.

22. Sivakami, A.P., Sudhira, P.H.: Management of recurrent inflammatory choroidal neovascular membrane secondary to Vogt-Koyanagi-Harada syndrome, using combined intravitreal injection of bevacizumab and triamcinolone acetate, Indian J Ophthalmol, 60; 2012, 6 : 551–552.

23. Soheilian, M., Aletaha, M., Yazdani, S. et al.: Management of pediatric Vogt-Koyanagi-Harada (VKH)-associated panuveitis. Ocul Immunol Inflamm, 2006; 14 : 91–98.

24. Wang Y., Gaudio P.A.: Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome. OculImmunol Inflamm, 16; 2008, 4 : 167–71.

25. Wu L., Evans T., Saravia M. et al.: Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome. Jpn J Ophthalmol, 53; 2009, 1 : 57-60.